The case for & against
Bull & Bear analysis
Fibro Animal Health Corporation (NASDAQ: PAHC) is a leading player in the animal health sector, specializing in a wide array of health and nutritional products for both livestock and companion animals. The company has effectively positioned itself to benefit from increasing global demand for sustainable and high-quality animal-derived proteins. Fibro's extensive product portfolio includes vaccines, nutritional specialties, and performance products, bolstered by the recent strategic acquisition of the Zoetis Medicated Feed Additives (MFA) business, enhancing its market influence and operational capabilities.
Bull says
- ↑Q3 revenue $291.2M (+13% YoY) with animal health sales up 26%.
- ↑Adjusted EBITDA grew 41% YoY to $67.7M; adjusted EPS +19%.
- ↑Generated $13M free cash flow over 12 months ended Mar 31, 2026.
- ↑MFA acquisition added $208M in sales, driving 54% segment growth.
- ↑FY26 net sales forecast raised to $1.46–$1.50B (+13–16%).
- ↑High profitability metrics and elevated earnings yield support valuation.
Bear says
- ↓Insiders net sold 39.7K shares; 13F institutional ownership score remains negative.
- ↓Analyst revisions are negative, hinting at downward earnings risks.
- ↓Tariff impact could add $5–$10M in costs, pressuring margins.
- ↓Post‐integration MFA growth may flatten to low-single digits.
- ↓Weak institutional interest and elevated volatility may drag stock.
- ↓Supply chain, tariff volatility, and regulatory shifts heighten risk.
Investment themes with PAHC
Drug development driving global healthcare solutions
Earnings Call · Q3 2026 · Mgmt. Guidance
Transcript signals
Bull points
- The animal health segment posted $291.2 million of net sales for the quarter, an increase of $32.8 million, or 13%, versus the same quarter prior year.
- We generated $13 million of positive free cash flow for the 12 months ended March 31, 2026.
- Our guidance for fiscal year 2026 is as follows. Net sales updated from a range of $1,450,000,000 to $1,500,000,000 to $1,460,000,000 to $1,500,000,000. This represents a growth range of 13% to 16% and a midpoint of approximately 14%. Total adjusted EBITDA updated from a range of $245 to $255 million to $247 to $255 million. This represents a growth range of 34 to 39 percent and a midpoint of approximately 37 percent.